Single-cell multi-omics platform provider Mission Bio has partnered with clinical diagnostic company Fulgent Genetics to expand the accessibility of single-cell multiomics for drug development and clinical research. The partnership with Fulgent Genetics will provide biopharmaceutical customers with more precise clinical trials, access to single-cell multi-omics expertise, and full solutions offered by Fulgent Genetics. 

The partnership will enable drug developers and researchers to use Mission Bio's Tapestri platform, in conjunction with Fulgent's other services for biomarker discovery, clinical research, and single-cell measurable residual disease (scMRD) diagnostic development at scale. Fulgent will offer single-cell multi-omics on the Tapestri Platform as part of its menu of services, with Fulgent also evaluating the potential use of the platform for clinical trials. The Tapestri Platform is currently available to customers through Fulgent Genetics' labs.

Mission Bio is a biotechnology company that specializes in developing and commercializing single-cell multi-omics solutions for precision medicine. The company's flagship product, the Tapestri Platform, allows researchers and clinicians to analyze individual cells and their genetic makeup with accuracy and resolution. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. It is being used by customers at research centers, pharmaceutical, and diagnostics companies to develop treatments and, eventually, cures for cancer.